Number of patients with laboratory abnormalities occurring in 15% or more of patients*
| Adverse event . | Dose level (mg.m2) . | Total N = 32 . | |||||||
|---|---|---|---|---|---|---|---|---|---|
| 3.5 N = 2 | 5 N = 1 | 7 N = 2 | 10 N = 5 | 14 N = 7 | 20 N = 3 | 28 N = 7 | 40 N = 5 | ||
| Anemia | |||||||||
| Grade 1 | 1/2 | 1/2 | 2/7 | 3/7 | 7/32 | ||||
| Grade 2 | 2/7 | 1/3 | 1/7 | 3/32 | |||||
| Grade 3 | |||||||||
| Grade 4 | |||||||||
| Thrombocytopenia | |||||||||
| Grade 1 | 1/7 | 5/7 | 6/32 | ||||||
| Grade 2 | 1/2 | 1/5 | 1/7 | 1/3 | 1/7 | 2/5 | 7/32 | ||
| Grade 3 | 1/7 | 1/32 | |||||||
| Grade 4 | 1/5 | 1/32 | |||||||
| Neutropenia | |||||||||
| Grade 2 | 1/7 | 1/3 | 2/32 | ||||||
| Grade 3 | 1/2 | 1/5 | 1/7 | 3/32 | |||||
| Grade 4 | 1/2 | 1/7 | 1/3 | 2/5 | 5/32 | ||||
| SGOT increased | |||||||||
| Grade 1 | 1/2 | 1/1 | 2/7 | 1/3 | 1/7 | 1/5 | 7/32 | ||
| Grade 2 | 2/7 | 1/3 | 3/32 | ||||||
| SGPT increased | |||||||||
| Grade 1 | 1/1 | 1/2 | 1/7 | 1/3 | 2/5 | 6/32 | |||
| Grade 2 | 1/2 | 1/7 | 2/32 | ||||||
| Decreased O2 saturation | |||||||||
| Grade 1 | 1/5 | 1/32 | |||||||
| Grade 2 | 1/7 | 1/32 | |||||||
| Grade 3 | 1/5 | 3/7 | 1/5 | 5/32 | |||||
| Adverse event . | Dose level (mg.m2) . | Total N = 32 . | |||||||
|---|---|---|---|---|---|---|---|---|---|
| 3.5 N = 2 | 5 N = 1 | 7 N = 2 | 10 N = 5 | 14 N = 7 | 20 N = 3 | 28 N = 7 | 40 N = 5 | ||
| Anemia | |||||||||
| Grade 1 | 1/2 | 1/2 | 2/7 | 3/7 | 7/32 | ||||
| Grade 2 | 2/7 | 1/3 | 1/7 | 3/32 | |||||
| Grade 3 | |||||||||
| Grade 4 | |||||||||
| Thrombocytopenia | |||||||||
| Grade 1 | 1/7 | 5/7 | 6/32 | ||||||
| Grade 2 | 1/2 | 1/5 | 1/7 | 1/3 | 1/7 | 2/5 | 7/32 | ||
| Grade 3 | 1/7 | 1/32 | |||||||
| Grade 4 | 1/5 | 1/32 | |||||||
| Neutropenia | |||||||||
| Grade 2 | 1/7 | 1/3 | 2/32 | ||||||
| Grade 3 | 1/2 | 1/5 | 1/7 | 3/32 | |||||
| Grade 4 | 1/2 | 1/7 | 1/3 | 2/5 | 5/32 | ||||
| SGOT increased | |||||||||
| Grade 1 | 1/2 | 1/1 | 2/7 | 1/3 | 1/7 | 1/5 | 7/32 | ||
| Grade 2 | 2/7 | 1/3 | 3/32 | ||||||
| SGPT increased | |||||||||
| Grade 1 | 1/1 | 1/2 | 1/7 | 1/3 | 2/5 | 6/32 | |||
| Grade 2 | 1/2 | 1/7 | 2/32 | ||||||
| Decreased O2 saturation | |||||||||
| Grade 1 | 1/5 | 1/32 | |||||||
| Grade 2 | 1/7 | 1/32 | |||||||
| Grade 3 | 1/5 | 3/7 | 1/5 | 5/32 | |||||
SGOT indicates serum glutamic oxaloacetic transaminase; and SGPT, serum glutamic pyruvic transaminase.
NCI CLL Working Group Criteria for Hematological Toxicity.